Cohava Gelber, PhD, MBA
Cohava Gelber, PhD, MBA, is an executive with over 25 years of experience in discovery and development of immune therapeutics and diagnostics for cancer, autoimmune disease, allergies and infectious diseases. Dr. Gelber held various executive positions in academia (Duke University) and biopharmaceutical companies (ImmuLogic Pharmaceutical Corporation, Molecular Discoveries and MannKind Corporation). Throughout her accomplished career, Dr. Gelber has pioneered and built various science companies, departments and proprietary platform technologies.
Dr. Gelber has founded Caerus Discovery with support from Biowa/ Kyowa Hakko Kirin and ImmunoCellular Therapeutics, Inc, Serpin Pharma and Orpheus, Inc. with investment made by angels, family offices and federal grants.
Prior to founding the above companies, Dr. Gelber served as the Chief Scientific & Technology Officer of ATCC (2005-2010), VP of R&D for MannKind Corp (MNKD)- a public company developing therapeutics for diabetes, cancer and autoimmune diseases (2001-2005). She was responsible for non-clinical development and clinical immune safety of drugs from pre-IND through phase III clinical trials. Dr. Gelber received her Ph.D. from the Weizmann Institute, her MBA degree from Cornell University and post doctorate training at Stanford University.
Dr. Gelber published numerous scientific manuscripts and textbook chapters and she is the inventor of 11 granted patents and 57 patent applications. Dr. Gelber is board member of Etubics, Serpin Pharma, Caerus Discovery and serves on the Scientific Advisory Board of George Mason University, Libraries, NeuroQuest, MicroVax and Immuno Cellular Therapeutics. Dr. Gelber is also an investor in numerous private companies including ContraFect, Serpin Pharma, Noblegen and Etubics (now NantCell).